The toxicity and mechanisms of pyrotinib on male reproductive system

Background: While Pyrotinib is effective in treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer, its impact on male reproductive health remains unclear. This study investigates the potential reproductive toxicity and underlying mechanisms of Pyrotinib in male Leydig cells, key regulators of testosterone production. Methods: Leydig cells were treated with Pyrotinib, with 0.1‰ dimethyl sulfoxide (DMSO)-treated cells serving as the control group, to evaluate its effects on cell viability, apoptosis, cell cycle progression and signaling pathways. Clonogenic assays, flow cytometry, Western blotting and transcriptome sequencing were employed. Results: Pyrotinib treatment for 24 hours significantly reduced cell viability and colony formation while increasing apoptosis. Flow cytometry revealed G1 phase arrest in 67.2% of cells after Pyrotinib exposure. Western blot analysis showed transient activation of Ak strain transforming (AKT) and extracellular signal-regulated kinase (ERK) at 2 hours, followed by marked inhibition at 24–48 hours. Transcriptomic analysis identified 197 downregulated genes enriched in chromatin organization and mitotic processes, particularly cell cycle regulation. Conclusions: Pyrotinib impairs Leydig cell proliferation through G1 arrest and inhibition of the phosphoinositide 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK)/ERK pathways, along with downregulation of cell cycle-related genes. These findings highlight the need for further evaluation of Pyrotinib’s reproductive safety in male patients.

Pyrotinib; Toxicity; Male; Leydig cells; Proliferation

[1] Ziegengeist JL, Tan AR. A clinical review of subcutaneous trastuzumab and the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the treatment of HER2-positive breast cancer. Clinical Breast Cancer. 2025; 25: e124–e132.

[2] Stanowicka-Grada M, Senkus E. Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Current Treatment Options in Oncology. 2023; 24: 1633–1650.

[3] Qi X, Shi Q, Xuhong J, Zhang Y, Jiang J. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now. Breast Cancer Research. 2023; 25: 113.

[4] Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of Clinical Oncology. 2017; 35: 3105–3112.

[5] Li X, Yang C, Wan H, Zhang G, Feng J, Zhang L, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. European Journal of Pharmaceutical Sciences. 2017; 110: 51–61.

[6] Zhang Q, He P, Tian T, Yan X, Huang J, Zhang Z, et al. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: a prospective real-world study. Frontiers in Pharmacology. 2023; 14: 1100556.

[7] Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, et al. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nature Medicine. 2023; 29: 2079–2086.

[8] Liu D, Kou F, Gong J, Wang Z, Zhang X, Li J, et al. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: a dose-escalation phase I study. Cancer Medicine. 2023; 12: 10704–10714.

[9] Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018; 34: i884–i890.

[10] Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nature Methods. 2015; 12: 357–360.

[11] Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014; 30: 923–930.

[12] Lê S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis. Journal of Statistical Software. 2008; 25: 1–18.

[13] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014; 15: 550.

[14] Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biology. 2010; 11: R14.

[15] Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research. 2000; 28: 27–30.

[16] Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS: A Journal of Integrative Biology. 2012; 16: 284–287.

[17] Song Z, Lv D, Chen SQ, Huang J, Li Y, Ying S, et al. Pyrotinib in patients with HER2-amplified advanced non-small cell lung cancer: a prospective, multicenter, single-arm trial. Clinical Cancer Research. 2022; 28: 461–467.

[18] Wang L, Wu Y, Ren Z, Chu X, Chen J, Liu L, et al. A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations. Cancer Medicine. 2024; 13: e7335.

[19] Meng J, Liu XY, Ma S, Zhang H, Yu SD, Zhang YF, et al. Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein. Acta Pharmacologica Sinica. 2019; 40: 980–988.

[20] Zirkin BR, Papadopoulos V. Leydig cells: formation, function, and regulation. Biology of Reproduction. 2018; 99: 101–111.

[21] Zhou L, Le K, Chen Q, Wang H. The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma. BMC Oral Health. 2024; 24: 898.

[22] Wu L, Huang S, Tian W, Liu P, Xie Y, Qiu Y, et al. PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer. Cell Death Discovery. 2024; 10: 7.

[23] Ou X, Tan Y, Xie J, Yuan J, Deng X, Shao R, et al. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer. Drug Resistance Updates. 2024; 73: 101063.

[24] Zhang HP, Jiang RY, Zhu JY, Sun KN, Huang Y, Zhou HH, et al. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024; 31: 539–551.

[25] Zhang K, Hong R, Kaping L, Xu F, Xia W, Qin G, et al. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. Cancer Letters. 2019; 447: 130–140.

[26] Chen H, Si Y, Wen J, Hu C, Xia E, Wang Y, et al. P110alpha inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer. Neoplasia. 2023; 43: 100913.

[27] Orta-Yilmaz B, Korkut A, Aydin Y. The impact of furan exposure on steroidogenesis in Leydig cells: cellular and molecular observations. Molecular Biology Reports. 2024; 51: 1047.

[28] Leisegang K, Henkel R. The in vitro modulation of steroidogenesis by inflammatory cytokines and insulin in TM3 Leydig cells. Reproductive Biology and Endocrinology. 2018; 16: 26.

[29] Tian M, Cao H, Gao H, Zhu L, Wu Y, Li G. Rotenone-induced cell apoptosis via endoplasmic reticulum stress and PERK-eIF2alpha-CHOP signalling pathways in TM3 cells. Ecotoxicology and Environmental Safety. 2024; 284: 116972.